Valvular & structural heart disease
Clinical Outcomes of a Dedicated TAVR Device for Native Aortic Regurgitation: Insights From a Multicenter Real-World Experience
Authors' conclusion
In this large analysis, transfemoral transcatheter aortic valve replacement with the Trilogy valve demonstrated high procedural success and favorable hemodynamic valve performance. These findings are encouraging and suggest a potential role for the Trilogy valve in patients with symptomatic aortic regurgitation who are unsuitable for surgery.
Study context
- Population
- Patients with symptomatic aortic regurgitation who underwent transfemoral TAVR with the JenaValve Trilogy valve between June 2021 and June 2025patients included
- Participants
- 363 patients
- Outcome
- Transfemoral access
Methodological details8 European centers, outcomes defined per VARC-3
- 8 European centers
- Outcomes defined per VARC-3
Main finding
As reported in the abstract
Trilogy
99%
359 of 363
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Technical success | Trilogy 98% |
| Valve embolization | Trilogy 5 events · of the 5, managed with a second valve 2 · of the 5, managed surgically 2 · of the 5, required valve-in-valve reintervention 1 |
| None or trace leakage · discharge | Trilogy 86% |
| Transvalvular gradient · discharge | Trilogy mean 4 mm Hg |
| New York Heart Association class I or II · 30 days | Trilogy 88% |
| All-cause mortality (Kaplan-Meier estimated) · 6 months, 1, 2, and 3 yearsAmong patients with available follow-up | Trilogy 6 months 4.1% · 1 year 7.0% · 2 years 15.8% · 3 years 25.9% |
Additional technical failures
- Two additional technical failures involved hemodynamic instability and a vascular complication
- Two
Safety
| Outcome | Values |
|---|---|
| Permanent pacemaker implantation | Trilogy 22% |
| In-hospital mortality | Trilogy 0.3% |
Original publication
Clinical Outcomes of a Dedicated TAVR Device for Native Aortic Regurgitation: Insights From a Multicenter Real-World Experience. Circ Cardiovasc Interv. Published 10 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →